Study: Randomized phase III trial comparing sacituzumab govitecan plus pembrolizumab with pembrolizumab alone in untreated metastatic NSCLC with PD-L1 TPS ≥50%.

Key data: Median centrally reviewed PFS was 11.8 versus 7.7 months; HR 0.81 (95% CI 0.66–1.00), P=0.0252, missing the prespecified threshold. Interim OS was 21.5 versus 22.8 months; HR 1.07 (95% CI 0.85–1.35). Grade ≥3 treatment-related adverse events occurred in 55.7% versus 16.5%.

Key data: Median centrally reviewed PFS was 11.8 versus 7.7 months; HR 0.81 (95% CI 0.66–1.00), P=0.0252, missing the prespecified threshold. Interim OS was 21.5 versus 22.8 months; HR 1.07 (95% CI 0.85–1.35). Grade ≥3 treatment-related adverse events occurred in 55.7% versus 16.5%.

Why it matters: The findings argue against adding this ADC to pembrolizumab in this setting.

Clinical context & caveats: OS is interim; the nonsignificant result does not establish equivalence.

Study: Final phase III analysis comparing perioperative atezolizumab plus platinum-based chemotherapy with control in resectable NSCLC.

Key data: Median EFS was 62.8 versus 34.9 months, but the predefined significance threshold was not met. Major pathological response was 54.3% versus 24.9%.

Why it matters: This negative result cautions against assuming that different perioperative immunotherapy regimens provide interchangeable evidence.

Clinical context & caveats: Favorable median EFS and pathological response differences do not establish efficacy when the primary statistical threshold is missed.

Study: Randomized phase III trial evaluating local consolidative therapy plus continued nivolumab/ipilimumab versus nivolumab/ipilimumab alone after induction.

Key data: Among 166 randomized patients, median OS with versus without local consolidation was 43.2 versus 52.8 months; HR 1.14 (95% CI 0.75–1.74). Median PFS was 31.3 versus 24.3 months; HR 0.79 (95% CI 0.54–1.15).

Why it matters: The findings argue against routine local consolidation solely to improve survival after this systemic regimen.

Caveat: The results should not be generalized to every oligometastatic setting or interpreted as proof of equivalence.

Study: Final OS analysis of a randomized phase III trial comparing first-line amivantamab plus carboplatin–pemetrexed with chemotherapy in advanced EGFR exon 20 insertion NSCLC.

Key data: Median intention-to-treat OS was 34.3 versus 27.9 months; HR 0.87 (95% CI 0.66–1.14). Among 128 progressing controls, 97 (76%) crossed over. Separately, the crossover-adjusted IPCW HR was 0.57 (95% CI 0.39–0.82).

Why it matters: The update informs interpretation of upfront treatment when many control patients subsequently receive the targeted agent.

Caveat: Model-dependent crossover adjustment cannot replace the nonsignificant randomized intention-to-treat result.

Study: Exploratory eight-year OS update from the randomized phase III trial of adjuvant osimertinib versus placebo in completely resected EGFR-mutated stage IB–IIIA NSCLC.

Key data: Eight-year OS in stage II–IIIA was 74% versus 58%; HR 0.53 (95% CI 0.38–0.75). Across stage IB–IIIA, it was 79% versus 64%; HR 0.52 (95% CI 0.39–0.71).

Why it matters: The findings strengthen long-term counseling about the survival benefit of adjuvant treatment.

Clinical context & caveats: This exploratory update lacked additional survival data for 127 patients, who retained their earlier censoring.

Study: Randomized phase III trial comparing the B7-H3 antibody–drug conjugate tambotatug pelitecan with topotecan in relapsed SCLC.

Key data: At the prespecified interim analysis, median OS was 13.3 versus 9.4 months; HR 0.46 (95% CI 0.35–0.62). Investigator-assessed PFS was 7.4 versus 2.8 months; HR 0.29 (95% CI 0.23–0.37). Grade ≥3 all-cause adverse events occurred in 55.4% versus 77.9%.

Why it matters: Randomized survival evidence supports B7-H3-directed treatment as a potential option in relapsed SCLC.

Clinical context & caveats: Interim survival benefit against topotecan does not establish the preferred sequence among newer treatments.

Study: Randomized phase III trial comparing the B7-H3-directed ADC risvutatug rezetecan with topotecan in relapsed SCLC; more than 80% had received prior PD-(L)1 therapy.

Key data: Median OS was 18.5 versus 10.3 months; HR 0.46 (95% CI 0.35–0.62), P<0.0001. Centrally reviewed PFS was 7.2 versus 3.0 months; HR 0.33 (95% CI 0.25–0.42). Grade ≥3 treatment-related adverse events occurred in 60.9% versus 78.2%.

Why it matters: The prior immunotherapy exposure supports relevance after chemoimmunotherapy.

Clinical context & caveats: OS is interim, and cross-trial comparisons cannot establish superiority over other B7-H3-directed agents.

Study: Randomized phase III trial comparing MRI surveillance alone with MRI surveillance plus prophylactic cranial irradiation after initial SCLC treatment.

Key data: Among 304 randomized patients, cognitive failure-free survival HR was 0.60 (90% CI 0.46–0.78). Preliminary OS HR was 0.90 (90% CI 0.67–1.20). Grade 3–5 treatment-related adverse events occurred in 0.8% versus 7.9%.

Why it matters: The findings support discussing PCI omission alongside reliable MRI surveillance.

Clinical context & caveats: OS remains immature, with 128 deaths and final analysis planned at 190; survival noninferiority is not established.

Study: Prespecified interim OS analysis of a randomized trial comparing first-line ivonescimab with pembrolizumab in advanced NSCLC with PD-L1 ≥1%.

Key data: Among 398 randomized patients, median OS was 30.8 versus 22.6 months; HR 0.73 (95% CI 0.57–0.95), after 234 deaths. The congress report described the OS benefit as statistically significant.

Why it matters: The survival update strengthens the clinical rationale for combined PD-1/VEGF blockade.

Clinical context & caveats: OS is interim, and the China-only population and pembrolizumab-monotherapy comparator limit extrapolation to other populations and treatment choices.

Study: Randomized phase III trial comparing trastuzumab deruxtecan with pembrolizumab plus platinum–pemetrexed in untreated advanced HER2-mutated NSCLC.

Key data: Centrally reviewed median PFS was 14.3 versus 8.3 months; HR 0.63 (95% CI 0.50–0.79), P<0.0001. Median OS was 29.3 versus 33.1 months; HR 1.15 (95% CI 0.88–1.52). Drug-related ILD occurred in 20.8% versus 2.3%.

Why it matters: These results support considering HER2-directed treatment earlier in the disease course.

Clinical context & caveats: No OS benefit is established, and ILD remains an important safety consideration when weighing treatment sequence.

Study: Randomized phase III trial comparing zipalertinib plus platinum–pemetrexed with chemotherapy alone in advanced EGFR exon 20 insertion NSCLC.

Key data: Centrally reviewed median PFS was 14.5 versus 8.5 months; HR 0.50 (95% CI 0.34–0.73), P=0.00015. ORR was 65.0% versus 40.3%. Grade ≥3 adverse events occurred in 87.1% versus 54.4%.

Why it matters: The findings support a further first-line targeted combination for this molecular subgroup.

Clinical context & caveats: Interim OS is immature at 30% maturity—HR 0.72 (95% CI 0.42–1.23)—and the PFS benefit comes with increased toxicity.

Study: Single-arm phase I/II evaluation of zidesamtinib in TKI-naive advanced ROS1-positive NSCLC; up to one prior chemotherapy or immunotherapy line was permitted.

Key data: Blinded independent central review ORR was 94% (88/94 efficacy-evaluable patients); the 12-month duration-of-response rate was 86%. Intracranial ORR was 100% among 10 evaluable patients.

Why it matters: The findings support further evaluation of zidesamtinib earlier in the treatment sequence, including for CNS disease.

Clinical context & caveats: This single-arm phase I/II study cannot establish comparative efficacy, and the intracranial analysis includes only 10 patients.

Escalation requires regimen-specific evidence. EVOKE-03, IMpower030 and LONESTAR show why adding systemic or local treatment cannot be assumed to improve outcomes.

PFS gains need a wider clinical assessment. Toxicity, survival uncertainty and subsequent treatment choices matter when moving targeted therapies earlier.

Crossover changes interpretation, not the randomized result. PAPILLON illustrates why intention-to-treat OS and model-adjusted estimates must remain distinct.

SCLC management is evolving on two fronts. B7-H3-directed therapies may improve survival, while MRI surveillance may reduce cognitive harm; sequencing and final survival evidence remain important.

Response activity and durable survival are different milestones. ARROS-1 supports further development, while ADAURA illustrates the value of long-term follow-up.